Literature DB >> 16963490

Rhythm control and cardioversion.

N Sulke1, F Sayers, G Y H Lip.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16963490      PMCID： PMC1861343          DOI： 10.1136/hrt.2006.099879

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  47 in total

Review 1.  Theory and practice of defibrillation: (1) Atrial fibrillation and DC conversion.

Authors:  A A J Adgey; S J Walsh
Journal:  Heart       Date:  2004-12       Impact factor: 5.994

2.  Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence.

Authors:  Gerhard Hindricks; Christopher Piorkowski; Hildegard Tanner; Richard Kobza; Jin-Hong Gerds-Li; Corrado Carbucicchio; Hans Kottkamp
Journal:  Circulation       Date:  2005-07-11       Impact factor: 29.690

3.  Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial.

Authors:  Oussama M Wazni; Nassir F Marrouche; David O Martin; Atul Verma; Mandeep Bhargava; Walid Saliba; Dianna Bash; Robert Schweikert; Johannes Brachmann; Jens Gunther; Klaus Gutleben; Ennio Pisano; Dominico Potenza; Raffaele Fanelli; Antonio Raviele; Sakis Themistoclakis; Antonio Rossillo; Aldo Bonso; Andrea Natale
Journal:  JAMA       Date:  2005-06-01       Impact factor: 56.272

4.  Freedom from atrial tachyarrhythmias after catheter ablation of atrial fibrillation: a randomized comparison between 2 current ablation strategies.

Authors:  Martin R Karch; Bernhard Zrenner; Isabel Deisenhofer; Jürgen Schreieck; Gjin Ndrepepa; Jun Dong; Katrin Lamprecht; Petra Barthel; Etienne Luciani; Albert Schömig; Claus Schmitt
Journal:  Circulation       Date:  2005-05-31       Impact factor: 29.690

5.  Efficacy of transthoracic cardioversion of atrial fibrillation using a biphasic, truncated exponential shock waveform at variable initial shock energies.

Authors:  Eric J Rashba; Michael R Gold; Fred A Crawford; Robert B Leman; Robert W Peters; Stephen R Shorofsky
Journal:  Am J Cardiol       Date:  2004-12-15       Impact factor: 2.778

6.  Sotalol versus propafenone for long-term maintenance of normal sinus rhythm in patients with recurrent symptomatic atrial fibrillation.

Authors:  George E Kochiadakis; Nikos E Igoumenidis; Michail E Hamilos; Panagiotis G Tzerakis; Nikos C Klapsinos; Gregory I Chlouverakis; Panos E Vardas
Journal:  Am J Cardiol       Date:  2004-12-15       Impact factor: 2.778

7.  Effects of diltiazem pretreatment on direct-current cardioversion in patients with persistent atrial fibrillation: a single-blind, randomized, controlled study.

Authors:  G Q Villani; M F Piepoli; C Terracciano; A Capucci
Journal:  Am Heart J       Date:  2000-09       Impact factor: 4.749

8.  Amiodarone versus sotalol for atrial fibrillation.

Authors:  Bramah N Singh; Steven N Singh; Domenic J Reda; X Charlene Tang; Becky Lopez; Crystal L Harris; Ross D Fletcher; Satish C Sharma; J Edwin Atwood; Alan K Jacobson; H Daniel Lewis; Dennis W Raisch; Michael D Ezekowitz
Journal:  N Engl J Med       Date:  2005-05-05       Impact factor: 91.245

9.  Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach.

Authors:  Paolo Alboni; Giovanni L Botto; Nicola Baldi; Mario Luzi; Vitantonio Russo; Lorella Gianfranchi; Paola Marchi; Massimo Calzolari; Alberto Solano; Raffaele Baroffio; Germano Gaggioli
Journal:  N Engl J Med       Date:  2004-12-02       Impact factor: 91.245

10.  Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized, double-blinded trial.

Authors:  R H Falk; A A Knowlton; S A Bernard; N E Gotlieb; N J Battinelli
Journal:  Ann Intern Med       Date:  1987-04       Impact factor: 25.391
View more
  4 in total

1.  Practical Implementation of Anticoagulation Strategy for Patients Undergoing Cardioversion of Atrial Fibrillation.

Authors:  Andreas Goette; Hein Heidbuchel
Journal:  Arrhythm Electrophysiol Rev       Date:  2017-06

2.  Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial.

Authors:  Stefan H Hohnloser; Riccardo Cappato; Michael D Ezekowitz; Thomas Evers; Kurtulus Sahin; Paulus Kirchhof; Isabelle Ling Meng; Martin van Eickels; A John Camm
Journal:  Europace       Date:  2015-10-20       Impact factor: 5.214

3.  Comparing the delay with different anticoagulants before elective electrical cardioversion for atrial fibrillation/flutter.

Authors:  Christopher Wall; Tania Jankowski; Vinci Naruka; Paula Mota
Journal:  PLoS One       Date:  2019-01-03       Impact factor: 3.240

4.  Optogenetic Stimulation Using Anion Channelrhodopsin (GtACR1) Facilitates Termination of Reentrant Arrhythmias With Low Light Energy Requirements: A Computational Study.

Authors:  Alexander R Ochs; Thomas V Karathanos; Natalia A Trayanova; Patrick M Boyle
Journal:  Front Physiol       Date:  2021-08-30       Impact factor: 4.566
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.